Vertaling van "disease progresses " (Nederlands → Frans) :

TERMINOLOGIE

central-core-disease | congenitale spierdystrofie | NNO | congenitale spierdystrofie | met specifieke morfologische-afwijkingen van spiervezel | fibre-type disproportion | minicore disease | multicore disease | myopathie | myotubulair (centronucleair) | myopathie | nemaline lichaampjes
Disproportion des types de fibres Dystrophie musculaire congénitale:SAI | avec anomalies morphologiques spécifiques des fibres musculaires | Myopathie:à axe central | à bâtonnets [némaline] | de type: mini-core | multi-core | myotubulaire (centro-nucléaire)

ziekte van Franklin | gamma heavy chain disease | Mmu heavy chain disease
Maladie de Franklin

ADTKD-UMOD - UMOD-related autosomal dominant tubulointerstitial kidney disease
néphropathie tubulo-interstitielle autosomique dominante associée à UMOD

ADTKD-MUC1 - MUC1-related autosomal dominant tubulointerstitial kidney disease
néphropathie tubulo-intersitielle autosomique dominante associée à MUC1

bovien mucosal disease-virus
virus Bovine mucosal disease

Border disease-virus
virus Border disease

Borna disease-virus
virus Borna disease

AIED - Åland Islands eye disease
maladie ophtalmique des îles Åland

ADPCLD - autosomal dominant polycystic liver disease
polykystose hépatique isolée

Nairobi sheep disease-virus
virus Nairobi sheep disease

IN-CONTEXT TRANSLATIONS

“AD caregivers are typically the first to notice when their loved one’s symptoms are becoming worse and whether the disease may be progressing to the next stage, which is why caregivers are essential partners in disease management discussions,” said Barry W. Rovner, M.D., director of the Division of Geriatric Psychiatry and professor in the departments of Neurology and Psychiatry at Thomas Jefferson University, Philadelphia.
“AD caregivers are typically the first to notice when their loved one’s symptoms are becoming worse and whether the disease may be progressing to the next stage, which is why caregivers are essential partners in disease management discussions,” said Barry W. Rovner, M.D., director of the Division of Geriatric Psychiatry and professor in the departments of Neurology and Psychiatry at Thomas Jefferson University , Philadelphia .

Alzheimer’s Disease Caregivers Identify Memory Loss, Personal Safety And Confusion As Top Three Concerns Related To Progression Of Their Loved One’s Disease
Alpine Mountaineer And Alzheimer’s Advocate To Climb Highest Peak On Each Continent To Raise Awareness Of Growing Prevalence And Burden Of Alzheimer’s Disease

“In the face of this devastating chronic and progressive disease, it is important for AD caregivers to know about the available educational resources, support networks and treatments in order to enhance these discussions at all stages of the disease”.
“In the face of this devastating chronic and progressive disease, it is important for AD caregivers to know about the available educational resources, support networks and treatments in order to enhance these discussions at all stages of the disease ”.

Afinitor (USD 38 million), an oral inhibitor of the mTOR pathway, received European approval in August 2009 for use in patients with advanced renal cell carcinoma (RCC, kidney cancer) whose disease progressed on or after treatment with VEGF-targeted therapy.
Afinitor (USD 38 millions), inhibiteur par voie orale de la voie mTOR, a obtenu son autorisation dans l’Union européenne en tant que traitement du carcinome avancé des cellules rénales (cancer du rein) chez les malades où le carcinome a progressé pendant ou après un traitement ciblé sur le VEGF.

In de POPADAD-studie (Prevention of Progression of Arterial Disease and Diabetes Study Group), een gerandomiseerde gecontroleerde dubbelblinde studie bij patiënten met type 2-diabetes met asymptomatische perifere arteriopathie – en zonder symptomatische cardiovasculaire aandoening – werd met acetylsalicylzuur (100 mg p.d) en/of anti-oxidantia, na een gemiddelde follow-up van ongeveer 6,5 jaar, geen daling van het cardiovasculaire risico of van de mortaliteit gezien [ Brit Med J 2008; 337: a1840 met editoriaal : a1806 ].
Dans l’étude POPADAD (Prevention of Progression of Arterial Disease and Diabetes Study Group), une étude randomisée contrôlée en double aveugle, ayant inclus des patients diabétiques de type 2 présentant une artériopathie périphérique asymptomatique- et sans affection cardio-vasculaire symptomatique- l’administration d’acide acétylsalicylique (100 mg p.j) et/ou d’antioxydants n’a pas diminué le risque cardio-vasculaire, ni la mortalité après un suivi moyen d’environ 6,5 ans [ Brit Med J 2008; 337: a1840 avec éditorial : a1806 ].

“These survey results reveal that changes in cognition as the disease progresses were an important concern among caregivers,” said Eric J. Hall, president and Chief Executive Officer of AFA.
“ These survey results reveal th at changes in cognition as the disease progresses were an important concern among caregivers ,” said Eric J. Hall, president and Chief Executive Officer of AFA.

R.W. Schrier en R.O. Estacio: The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials (Editoriaal) Ann Intern Med 135 : 138-139(2001)
R.W. Schrier en R.O. Estacio: The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials (Editorial) Ann Intern Med 135 : 138-139(2001)